丹参及其主要成分对肺纤维化作用机制的研究进展
Research Progress on the Mechanism of Action of Salvia miltiorrhiza and Its Main Components on Pulmonary Fibrosis
DOI: 10.12677/acm.2024.14113006, PDF,   
作者: 张少琪, 杨善军*：黑龙江中医药大学附属第二医院肺病科，黑龙江 哈尔滨
关键词: 丹参；肺纤维化；作用机制；Salvia miltiorrhiza； Pulmonary Fibrosis； Mechanism of Action
摘要: 肺纤维化是由于肺组织遭到破坏，正常结构被大量纤维细胞所取代，并产生由胶原蛋白等组成的细胞外基质，影响肺通气功能，导致呼吸困难等一系列症状，极大地影响了人体健康与日常生活。其病因未完全明确，且目前临床治疗手段较为有限，效果不佳。因此，寻找有效且安全的治疗药物是研究的主要方向。丹参是一味活血化瘀的佳品，现已从中提取出多种有效药理成分如丹参素、丹参酮IIA、丹参酚酸、隐丹参酮等，可通过作用于多种信号机制，以此抑制肺纤维化的形成。本文对现有相关研究进行综合整理，以期为今后丹参应用于肺纤维化的临床治疗提供可靠的理论依据。
Abstract: Pulmonary fibrosis is caused by the destruction of lung tissue, where the normal structure is replaced by a large number of fibroblasts and an extracellular matrix composed of collagen is produced, which affects lung ventilation function and leads to a series of symptoms such as breathing difficulties, greatly affecting human health and daily life. The etiology is not fully understood, and currently clinical treatment methods are limited, resulting in poor efficacy. Therefore, finding effective and safe therapeutic drugs is the main direction of research. Salvia miltiorrhiza is a great herb for promoting blood circulation and removing blood stasis. Various effective pharmacological components have been extracted from it, such as danshensu, tanshinone IIA, salvianolic acid, cryptotanshinone, etc. It can inhibit the formation of pulmonary fibrosis by acting on various signaling mechanisms. This article comprehensively summarizes existing relevant research in order to provide reliable theoretical basis for the clinical treatment of pulmonary fibrosis using Danshen in the future.
文章引用：张少琪, 杨善军. 丹参及其主要成分对肺纤维化作用机制的研究进展[J]. 临床医学进展, 2024, 14(11): 1228-1234. https://doi.org/10.12677/acm.2024.14113006

参考文献

[1] Noble, P.W., Barkauskas, C.E. and Jiang, D. (2012) Pulmonary Fibrosis: Patterns and Perpetrators. Journal of Clinical Investigation, 122, 2756-2762. [Google Scholar] [CrossRef] [PubMed]
[2] Maher, T.M., Bendstrup, E., Dron, L., Langley, J., Smith, G., Khalid, J.M., et al. (2021) Global Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. Respiratory Research, 22, Article No. 197. [Google Scholar] [CrossRef] [PubMed]
[3] Rivera-Ortega, P., Hayton, C., Blaikley, J., Leonard, C. and Chaudhuri, N. (2018) Nintedanib in the Management of Idiopathic Pulmonary Fibrosis: Clinical Trial Evidence and Real-World Experience. Therapeutic Advances in Respiratory Disease, 12, Article 1753466618800618. [Google Scholar] [CrossRef] [PubMed]
[4] Singh, S. and Wairkar, S. (2023) Long-circulating Thiolated Chitosan Nanoparticles of Nintedanib with N-Acetyl Cysteine for Treating Idiopathic Pulmonary Fibrosis: In Vitro Assessment of Cytotoxicity, Antioxidant, and Antifibrotic Potential. International Journal of Pharmaceutics, 644, Article 123322. [Google Scholar] [CrossRef] [PubMed]
[5] 国家药典委员会. 中华人民共和国药典(第3部) [M]. 北京: 中国医药科技出版社, 2010.
[6] Yang, Z., Qi, J., Ping, D., Sun, X., Tao, Y., Liu, C., et al. (2022) Salvia Miltiorrhiza in Thorax and Abdominal Organ Fibrosis: A Review of Its Pharmacology. Frontiers in Pharmacology, 13, Article 999604. [Google Scholar] [CrossRef] [PubMed]
[7] Xu, Y., Lan, P. and Wang, T. (2023) The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Medicina, 59, Article 1984. [Google Scholar] [CrossRef] [PubMed]
[8] Gandhi, S., Tonelli, R., Murray, M., Samarelli, A.V. and Spagnolo, P. (2023) Environmental Causes of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 24, Article 16481. [Google Scholar] [CrossRef] [PubMed]
[9] Ma, Y., Cui, F., Li, D., Wang, J., Tang, L., Xie, J., et al. (2023) Lifestyle, Genetic Susceptibility, and the Risk of Idiopathic Pulmonary Fibrosis. Chest, 164, 929-938. [Google Scholar] [CrossRef] [PubMed]
[10] 张仲景. 金匮要略方论[M]. 北京: 人民卫生出版社, 1978.
[11] 陈云凤, 刘洪, 李群英, 等. 补肺益肾、化瘀通络法治疗特发性肺间质纤维化的临床研究[J]. 中华中医药杂志, 2014, 29(9): 3030-3032.
[12] 杨善军, 祝鹏宇, 王玥, 等. 基于NF-κB信号转导通路探讨加味补阳还五汤对肺纤维化小鼠的治疗作用[J]. 新疆医科大学学报, 2020, 43(3): 329-334.
[13] King, T.E., Pardo, A. and Selman, M. (2011) Idiopathic Pulmonary Fibrosis. The Lancet, 378, 1949-1961. [Google Scholar] [CrossRef] [PubMed]
[14] Tang, H., He, H., Ji, H., Gao, L., Mao, J., Liu, J., et al. (2015) Tanshinone IIA Ameliorates Bleomycin-Induced Pulmonary Fibrosis and Inhibits Transforming Growth Factor-Beta-Β-Dependent Epithelial to Mesenchymal Transition. Journal of Surgical Research, 197, 167-175. [Google Scholar] [CrossRef] [PubMed]
[15] 李金莲, 张海静, 高云航, 等. 丹参有效成分对TGF-β_1诱导的肺上皮细胞间质转化的影响[J]. 中国实验方剂学杂志, 2020, 26(5): 54-59.
[16] Liu, Q., Chu, H., Ma, Y., Wu, T., Qian, F., Ren, X., et al. (2016) Salvianolic Acid B Attenuates Experimental Pulmonary Fibrosis through Inhibition of the TGF-Β Signaling Pathway. Scientific Reports, 6, Article No. 27610. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, Q., Gan, C., Liu, H., Wang, L., Li, Y., Tan, Z., et al. (2020) Cryptotanshinone Reverses the Epithelial-Mesenchymal Transformation Process and Attenuates Bleomycin-Induced Pulmonary Fibrosis. Phytotherapy Research, 34, 2685-2696. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, H., Zhang, X., Shao, Y., Lin, X., Dong, F. and Liu, X. (2021) Danshensu Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting Lung Fibroblast-to-Myofibroblast Transition via the MEK/ERK Signaling Pathway. Bioengineered, 12, 3113-3124. [Google Scholar] [CrossRef] [PubMed]
[19] Gaikwad, A.V., Lu, W., Dey, S., Bhattarai, P., Haug, G., Larby, J., et al. (2023) Endothelial-to-Mesenchymal Transition: A Precursor to Pulmonary Arterial Remodelling in Patients with Idiopathic Pulmonary Fibrosis. ERJ Open Research, 9, 1-16. [Google Scholar] [CrossRef] [PubMed]
[20] Ackermann, M., Kim, Y.O., Wagner, W.L., Schuppan, D., Valenzuela, C.D., Mentzer, S.J., et al. (2017) Effects of Nintedanib on the Microvascular Architecture in a Lung Fibrosis Model. Angiogenesis, 20, 359-372. [Google Scholar] [CrossRef] [PubMed]
[21] Cao, Z., Lis, R., Ginsberg, M., Chavez, D., Shido, K., Rabbany, S.Y., et al. (2016) Targeting of the Pulmonary Capillary Vascular Niche Promotes Lung Alveolar Repair and Ameliorates Fibrosis. Nature Medicine, 22, 154-162. [Google Scholar] [CrossRef] [PubMed]
[22] Wang, R., Wang, Y., Hu, L., Lu, Z. and Wang, X. (2021) Inhibition of Complement C5a Receptor Protects Lung Cells and Tissues against Lipopolysaccharide-Induced Injury via Blocking Pyroptosis. Aging, 13, 8588-8598. [Google Scholar] [CrossRef] [PubMed]
[23] Yuan, T., Chen, Y., Zhang, H., Fang, L. and Du, G. (2017) Salvianolic Acid A, a Component of salvia Miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of Hpaecs Induced by Hypoxia. The American Journal of Chinese Medicine, 45, 1185-1200. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, Q., Shi, X., Tang, L., Xu, W., Jiang, S., Ding, W., et al. (2018) Salvianolic Acid B Attenuates Experimental Pulmonary Inflammation by Protecting Endothelial Cells against Oxidative Stress Injury. European Journal of Pharmacology, 840, 9-19. [Google Scholar] [CrossRef] [PubMed]
[25] 张人子, 李晟, 王导新. 隐丹参酮减轻LPS诱导的ARDS小鼠早期肺纤维化及机制研究[J]. 陆军军医大学学报, 2022, 44(18): 1819-1825+1834.
[26] 燕小宁, 张娜. 丹参下调早中期肺间质纤维化模型大鼠肺组织中VEGF的表达[J]. 临床医药实践, 2015, 24(6): 438-441.
[27] Boutros, M. and Ray, S. (2023) Oxidative Stress. Reference Module in Biomedical Sciences. Elsevier.
[28] Cameli, P., Carleo, A., Bergantini, L., Landi, C., Prasse, A. and Bargagli, E. (2019) Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis. Inflammation, 43, 1-7. [Google Scholar] [CrossRef] [PubMed]
[29] Peng, L., An, L., Sun, N., Ma, Y., Zhang, X., Liu, W., et al. (2019) salvia Miltiorrhiza Restrains Reactive Oxygen Species-Associated Pulmonary Fibrosis via Targeting Nrf2-Nox4 Redox Balance. The American Journal of Chinese Medicine, 47, 1113-1131. [Google Scholar] [CrossRef] [PubMed]
[30] 刘晓莹. 基于Notch1信号通路探讨丹酚酸A对人胚肺成纤维细胞MRC-5抗纤维化作用机制的研究[D]: [硕士学位论文]. 济南: 山东中医药大学, 2020.
[31] Xiao, Z., Liu, W., Mu, Y., Zhang, H., Wang, X., Zhao, C., et al. (2020) Pharmacological Effects of Salvianolic Acid B against Oxidative Damage. Frontiers in Pharmacology, 11, Article 572373. [Google Scholar] [CrossRef] [PubMed]
[32] An, L., Peng, L., Sun, N., Yang, Y., Zhang, X., Li, B., et al. (2019) Tanshinone IIA Activates Nuclear Factor-Erythroid 2-Related Factor 2 to Restrain Pulmonary Fibrosis via Regulation of Redox Homeostasis and Glutaminolysis. Antioxidants & Redox Signaling, 30, 1831-1848. [Google Scholar] [CrossRef] [PubMed]
[33] 徐华, 夏彬, 欧阳玉珍, 等. 丹参酮ⅡA通过iNOS缓解小鼠肺纤维化[J]. 基础医学与临床, 2016, 36(8): 1113-1117.
[34] 郭飞, 赵铭山. 丹参素对博莱霉素致大鼠肺纤维化的治疗作用[J]. 山东医药, 2011, 51(13): 24-25.
[35] Karamanos, N.K., Theocharis, A.D., Piperigkou, Z., Manou, D., Passi, A., Skandalis, S.S., et al. (2021) A Guide to the Composition and Functions of the Extracellular Matrix. The FEBS Journal, 288, 6850-6912. [Google Scholar] [CrossRef] [PubMed]
[36] Wynn, T. (2007) Cellular and Molecular Mechanisms of Fibrosis. The Journal of Pathology, 214, 199-210. [Google Scholar] [CrossRef] [PubMed]
[37] Meng, Y., Li, T., Zhou, G., Chen, Y., Yu, C., Pang, M., et al. (2015) The Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Axis Protects against Lung Fibroblast Migration and Lung Fibrosis by Inhibiting the Nox4-Derived Ros-Mediated Rhoa/rho Kinase Pathway. Antioxidants & Redox Signaling, 22, 241-258. [Google Scholar] [CrossRef] [PubMed]
[38] Meng, Y., Yu, C., Li, W., Li, T., Luo, W., Huang, S., et al. (2014) Angiotensin-Converting Enzyme 2/angiotensin-(1-7)/Mas Axis Protects against Lung Fibrosis by Inhibiting the MAPK/NF-κB Pathway. American Journal of Respiratory Cell and Molecular Biology, 50, 723-736. [Google Scholar] [CrossRef] [PubMed]
[39] Wu, H., Li, Y., Wang, Y., Xu, D., Li, C., Liu, M., et al. (2014) Tanshinone IIA Attenuates Bleomycin-Induced Pulmonary Fibrosis via Modulating Angiotensin-Converting Enzyme 2/Angiotensin-(1-7) Axis in Rats. International Journal of Medical Sciences, 11, 578-586. [Google Scholar] [CrossRef] [PubMed]
[40] Pan, Y., Fu, H., Kong, Q., Xiao, Y., Shou, Q., Chen, H., et al. (2014) Prevention of Pulmonary Fibrosis with Salvianolic Acid a by Inducing Fibroblast Cell Cycle Arrest and Promoting Apoptosis. Journal of Ethnopharmacology, 155, 1589-1596. [Google Scholar] [CrossRef] [PubMed]
[41] Luo, X., Deng, Q., Xue, Y., Zhang, T., Wu, Z., Peng, H., et al. (2021) Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-Βri/Smad Signaling. Molecules, 26, Article 1715. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, Y., Lu, W., Zhang, X., Lu, J., Xu, S., Chen, S., et al. (2019) Cryptotanshinone Protects against Pulmonary Fibrosis through Inhibiting Smad and STAT3 Signaling Pathways. Pharmacological Research, 147, Article 104307. [Google Scholar] [CrossRef] [PubMed]
[43] Jiang, Y., You, F., Zhu, J., Zheng, C., Yan, R. and Zeng, J. (2019) Cryptotanshinone Ameliorates Radiation-Induced Lung Injury in Rats. Evidence-Based Complementary and Alternative Medicine, 2019, 1-14. [Google Scholar] [CrossRef] [PubMed]
[44] Mahalanobish, S., Saha, S., Dutta, S. and Sil, P.C. (2020) Matrix Metalloproteinase: An Upcoming Therapeutic Approach for Idiopathic Pulmonary Fibrosis. Pharmacological Research, 152, Article 104591. [Google Scholar] [CrossRef] [PubMed]
[45] Yang, H., Cheng, H., Dai, R., Shang, L., Zhang, X. and Wen, H. (2023) Macrophage Polarization in Tissue Fibrosis. Peer Journal, 11, e16092. [Google Scholar] [CrossRef] [PubMed]
[46] Wynn, T.A. and Vannella, K.M. (2016) Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity, 44, 450-462. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, L., Zhang, Y., Zhang, N., Xia, J., Zhan, Q. and Wang, C. (2019) Potential Role of M2 Macrophage Polarization in Ventilator-Induced Lung Fibrosis. International Immunopharmacology, 75, Article 105795. [Google Scholar] [CrossRef] [PubMed]
[48] Shapouri-Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaeili, S., Mardani, F., et al. (2018) Macrophage Plasticity, Polarization, and Function in Health and Disease. Journal of Cellular Physiology, 233, 6425-6440. [Google Scholar] [CrossRef] [PubMed]
[49] Tarique, A.A., Logan, J., Thomas, E., Holt, P.G., Sly, P.D. and Fantino, E. (2015) Phenotypic, Functional, and Plasticity Features of Classical and Alternatively Activated Human Macrophages. American Journal of Respiratory Cell and Molecular Biology, 53, 676-688. [Google Scholar] [CrossRef] [PubMed]
[50] 王渐鸿. 基于THP-1与MRC-5细胞模型的丹酚酸B与丹参酮ⅡA抗肺纤维化作用研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2020.
[51] Zhao, J., Pu, J., Fan, J., Feng, X., Xu, J., Zhang, R., et al. (2022) Tanshinone IIA Prevents Acute Lung Injury by Regulating Macrophage Polarization. Journal of Integrative Medicine, 20, 274-280. [Google Scholar] [CrossRef] [PubMed]
[52] Ye, Z., Wang, P., Feng, G., Wang, Q., Liu, C., Lu, J., et al. (2023) Cryptotanshinone Attenuates LPS-Induced Acute Lung Injury by Regulating Metabolic Reprogramming of Macrophage. Frontiers in Medicine, 9, Article 1075465. [Google Scholar] [CrossRef] [PubMed]
[53] Schuliga, M., Grainge, C., Westall, G. and Knight, D. (2018) The Fibrogenic Actions of the Coagulant and Plasminogen Activation Systems in Pulmonary Fibrosis. The International Journal of Biochemistry & Cell Biology, 97, 108-117. [Google Scholar] [CrossRef] [PubMed]
[54] Kanno, Y. (2023) The uPA/uPAR System Orchestrates the Inflammatory Response, Vascular Homeostasis, and Immune System in Fibrosis Progression. International Journal of Molecular Sciences, 24, Article 1796. [Google Scholar] [CrossRef] [PubMed]
[55] Marudamuthu, A.S., Bhandary, Y.P., Shetty, S.K., Fu, J., Sathish, V., Prakash, Y., et al. (2015) Role of the Urokinase-Fibrinolytic System in Epithelial–mesenchymal Transition during Lung Injury. The American Journal of Pathology, 185, 55-68. [Google Scholar] [CrossRef] [PubMed]
[56] 李晗, 高云航, 宋玲, 等. 雾化吸入丹参有效成分对肺纤维化模型大鼠凝血纤溶系统的影响[J]. 时珍国医国药, 2023, 34(6): 1298-1301.
[57] 田淑霞, 陈珺明, 韩永龙, 等. 丹参酮对肺纤维化大鼠的干预作用及其机制研究[J]. 世界中医药, 2014, 9(12): 1647-1650.
[58] Burman, A., Tanjore, H. and Blackwell, T.S. (2018) Endoplasmic Reticulum Stress in Pulmonary Fibrosis. Matrix Biology, 68, 355-365. [Google Scholar] [CrossRef] [PubMed]
[59] Cheng, H., Feng, D., Li, X., Gao, L., Tang, S., Liu, W., et al. (2021) Iron Deposition-Induced Ferroptosis in Alveolar Type II Cells Promotes the Development of Pulmonary Fibrosis. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1867, Article 166204. [Google Scholar] [CrossRef] [PubMed]
[60] Zhao, H., Wang, Y., Qiu, T., Liu, W. and Yao, P. (2020) Autophagy, an Important Therapeutic Target for Pulmonary Fibrosis Diseases. Clinica Chimica Acta, 502, 139-147. [Google Scholar] [CrossRef] [PubMed]

为你推荐